Related references
Note: Only part of the references are listed.Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Xiaojun Liu et al.
CANCER RESEARCH (2015)
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Hillary G. Caruso et al.
CANCER RESEARCH (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
NK cell-based cancer immunotherapy: from basic biology to clinical application
Li Yang et al.
SCIENCE CHINA-LIFE SCIENCES (2015)
Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells
Darya Alizadeh et al.
CANCER RESEARCH (2014)
Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity
Tae Heung Kang et al.
CANCER RESEARCH (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation
Teppei Yamada et al.
PLOS ONE (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Cellular Immunotherapy for Carcinoma Using Genetically Modified EGFR-Specific T Lymphocytes
Xikun Zhou et al.
NEOPLASIA (2013)
Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment
Michael H. Kershaw et al.
ONCOIMMUNOLOGY (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Brian G. Till et al.
BLOOD (2012)
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
Zhili Zheng et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
Geoffrey R. Oxnard et al.
CLINICAL CANCER RESEARCH (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an in vitro model of ischaemia
Lisa McGinley et al.
STEM CELL RESEARCH & THERAPY (2011)
Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma
Masaki Anraku et al.
JOURNAL OF IMMUNOLOGY (2010)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer
Christopher G. Azzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach
Francesco Grossi et al.
ONCOLOGIST (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Combination of docetaxel and recombinant vaccine enhances T-Cell responses and antitumor activity: Effects of docetaxel on immune enhancement
Charlie T. Garnett et al.
CLINICAL CANCER RESEARCH (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go?
Pawel Muranski et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT1
G Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy
PF Robbins et al.
JOURNAL OF IMMUNOLOGY (2004)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Share Paper
